HRT in Perimenopause: Who’s a Candidate, Who Needs Contraception, and What to Avoid

Perimenopause is the stretch of months to years before menopause, when ovarian hormones fluctuate and cycles turn irregular. A lot of these patients will ask you about hormone therapy, and for the right candidate, HRT is safe and very effective for vasomotor and genitourinary symptoms.

The tricky part is the decision tree: who can use which therapy, whether she still needs contraception, and what to reach for if HRT is off the table. Here's a clinic-ready workflow.

Step 1: do they still need contraception?

• Most patients can stop contraception around age 51.
• Ask about sexual activity, a partner's vasectomy, or tubal ligation.
• The key point: HRT is not contraceptive. If pregnancy is possible, handle contraception first, then layer in symptom management.

Best contraception options in perimenopause:

• Levonorgestrel IUD: excellent for bleeding control, and you can pair it with systemic estrogen (like the estradiol patch) if needed.
• Progestin-only methods: POP (Slynd or norethindrone).
• Combined hormonal contraception (CHC): if she's eligible, it improves cycles and vasomotor symptoms.

For the full set of methods and the missed-dose rules, see the non-COC contraception guide.

Step 2: are they a candidate?

A) Contraindications to combined hormonal contraception (pill, ring, patch)

• Age 35 or older plus smoking 15 or more cigarettes/day
• Multiple major ASCVD risks (DM, HTN, smoking, older age)
• Uncontrolled hypertension
• History of VTE/DVT/PE
• Ischemic heart disease or stroke
• Complicated valvular disease
• Current or past breast cancer
• Severe liver disease/cirrhosis, hepatic tumors
• Migraine with aura
• Diabetes for 20 years or more, or with end-organ disease

If CHC is contraindicated, choose non-estrogen contraception (IUD or progestin-only pill) and manage symptoms separately, for example transdermal estradiol plus micronized progesterone if systemic estrogen is appropriate.

B) Contraindications and cautions for menopausal hormone therapy (estradiol patch, gel, or tablet plus or minus progestogen)

Absolute contraindications:

• Hormone receptor-positive breast cancer
• Active liver disease
• Prior stroke, VTE, or known thrombophilia
• Unexplained vaginal bleeding
• High-risk endometrial or ovarian cancer
• Recent MI

Use with caution, optimize first:

• High ASCVD risk: prefer transdermal estradiol (lower VTE risk than oral).
• Uncontrolled HTN, hyperlipidemia, or poorly controlled diabetes.
• Active smoking.
• Age 60 or older, or more than 10 years post-menopause (starting HRT then usually isn't preferred).

Decision flow for NPs

1. Still need contraception?
   • CHC eligible: consider CHC for both contraception and symptom relief.
   • CHC contraindicated: non-estrogen contraception (POP or IUD) plus symptom treatment. Consider an estradiol patch if appropriate.
2. No contraception needed (post-menopause or permanent contraception):
   • Symptomatic and no contraindications: consider HRT, preferring transdermal estradiol plus micronized progesterone if she has a uterus.
   • High risk: non-hormonal therapies (SSRIs/SNRIs, gabapentin, fezolinetant) plus or minus local vaginal estrogen for GSM.

Non-hormonal and alternative options

• Vasomotor symptoms: SSRIs (paroxetine, escitalopram), SNRIs (venlafaxine), gabapentin, fezolinetant.
• Genitourinary syndrome of menopause (GSM): low-dose vaginal estrogen (tablet, cream, or ring), minimal systemic absorption, no progestogen required.
• Cycle control plus contraception when CHC isn't an option: IUD plus transdermal estradiol.

Practical NP pearls

• Transdermal estradiol carries lower VTE risk than oral.
• An IUD gives you endometrial protection when paired with systemic estrogen.
• Start low, titrate to the lowest effective dose.
• Don't start systemic HRT for the first time in patients over 60 or more than 10 years post-menopause.
• Reassess at 4 to 8 weeks, then annually, sooner if risks change.

Safety checklist before starting

• Screen: BP, BMI, migraine with aura, VTE/stroke/MI history, breast and gyn history, liver disease, smoking, A1c and lipids.
• Confirm up-to-date breast, cervical, and colon cancer screening.
• Pregnancy test if cycles are present.
• Medication review for interactions (anticoagulants, enzyme inducers).

Frequently asked questions

Can HRT double as her birth control?
No. Menopausal hormone therapy doses don't suppress ovulation reliably. If pregnancy is still possible, she needs an actual contraceptive method alongside any symptom treatment.

She has migraine with aura but bad hot flashes. What now?
Skip combined hormonal contraception, since aura is a contraindication. For symptoms you can still consider transdermal estradiol if she's an HRT candidate, or go non-hormonal with an SSRI/SNRI, gabapentin, or fezolinetant. Pair with a progestin-only method or IUD if she still needs contraception.

Why transdermal over oral estrogen for higher-risk patients?
Transdermal estradiol carries a lower VTE risk than oral, which matters for patients with metabolic or cardiovascular risk. It's the safer default when you're optimizing first.

Is there an age cutoff for starting HRT?
Starting systemic HRT for the first time after 60, or more than 10 years out from menopause, generally isn't preferred. Within that window and symptomatic, a candidate without contraindications is reasonable to start.

If you want the upstream piece on symptoms, work-up, and starter doses, read perimenopause 101, and for the contraception side of this decision see the non-COC contraception guide. To keep the candidate-versus-avoid criteria on one page at your desk, the Clinical Desk Reference ($37) has it, and the Primary Care Clinical Mastery Program (AANP-accredited) goes deeper on the full primary care picture.

Education only. Use clinical judgment and your local guidelines.

Written by Allison Sowders, MSN, APRN, FNP-BC, a practicing primary care nurse practitioner and founder of Nurse Practitioner Mentor. Reviewed July 2026.